063 L’interféron α dans le traitement des lésions mélaniques de la conjonctive

Abstract

Melanocytic conjunctival lesions can be treated by controlled observation, surgery, irradiation, heat application, cryotherapy or topical chemotherapy. This non-comparative prospective case series reports on the first topical Interferon a-2b therapy for the treatment of melanocytic conjunctival lesions. 9 patients with histologically proven acquired melanosis with dysplasia and/or conjunctival melanoma have been treated with recombinant IFN a-2b (Intron A®, essex pharma). The agent was diluted under sterile conditions to 1 Mio IU/ml Intron A® and packed in single dose units (EDO) by the pharmacy. It was stored in the refrigerator and applied 5 × 1 drop/day topically by the patient for 6 weeks. The patients were seen after 2 weeks and after the end of the treatment. 9 lesions of 9 patients showed complete or almost complete regression and lost pigmentation. 4 patients were treated twice after the first therapy because of incomplete regression. Only one of those patients needed a third cycle of therapy to show stabile regression. The follow-up is 14 months (median). No local or systemic side effects were encountered. The pre- and post-therapy clinical pictures will be presented. Our observations suggest that topically applied Interferon a-2b might be an effective agent for the therapy of melanocytic conjunctival tumours with so far no adverse side effects. It might be an alternative to other more toxic chemotherapeutical agents. A prospective multicenter study will help to finally evaluate the potential of topical Interferon therapy for melanocytic conjunctival tumours, in particular PAM with atypia and minimal invasive conjunctival melanoma.